NS Partners Ltd Buys 900 Shares of Illumina, Inc. (NASDAQ:ILMN)

NS Partners Ltd grew its stake in Illumina, Inc. (NASDAQ:ILMN) by 2.5% during the 3rd quarter, Holdings Channel.com reports. The firm owned 37,103 shares of the life sciences company’s stock after acquiring an additional 900 shares during the period. NS Partners Ltd’s holdings in Illumina were worth $4,839,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently modified their holdings of the stock. Empowered Funds LLC grew its stake in shares of Illumina by 1.7% in the third quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company’s stock valued at $516,000 after acquiring an additional 66 shares in the last quarter. Caprock Group LLC raised its stake in Illumina by 3.0% in the 3rd quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company’s stock worth $376,000 after purchasing an additional 83 shares in the last quarter. UMB Bank n.a. boosted its holdings in Illumina by 7.0% in the 2nd quarter. UMB Bank n.a. now owns 1,341 shares of the life sciences company’s stock valued at $140,000 after purchasing an additional 88 shares during the period. Integrated Advisors Network LLC grew its position in shares of Illumina by 2.0% during the 3rd quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock worth $585,000 after purchasing an additional 90 shares in the last quarter. Finally, Carson Advisory Inc. increased its holdings in shares of Illumina by 3.8% during the third quarter. Carson Advisory Inc. now owns 2,757 shares of the life sciences company’s stock worth $360,000 after purchasing an additional 102 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Price Performance

Illumina stock opened at $135.00 on Wednesday. The firm has a market cap of $21.41 billion, a P/E ratio of -13.55 and a beta of 1.13. The stock’s 50 day moving average is $140.04 and its 200 day moving average is $124.47. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. Illumina, Inc. has a one year low of $93.39 and a one year high of $156.66.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The firm had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. During the same quarter in the previous year, the company earned $0.33 EPS. The company’s revenue for the quarter was down 3.5% on a year-over-year basis. As a group, research analysts expect that Illumina, Inc. will post 4.11 EPS for the current year.

Analysts Set New Price Targets

ILMN has been the subject of several recent research reports. HSBC upgraded Illumina from a “hold” rating to a “buy” rating and set a $180.00 price target for the company in a research note on Thursday, October 17th. Daiwa Capital Markets upgraded shares of Illumina from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $120.00 to $154.00 in a research note on Friday, August 16th. Morgan Stanley reissued an “equal weight” rating and issued a $156.00 price objective on shares of Illumina in a research note on Tuesday, November 12th. TD Cowen lifted their price target on Illumina from $166.00 to $177.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Finally, Daiwa America upgraded Illumina to a “strong-buy” rating in a research report on Friday, August 16th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $164.00.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.